Marie Montus
1 Bis Rue De L'Internationale
Evry, 91000, France
Evry, 91000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy.
Journal: Molecular therapy. Methods & clinical development
Published: March 06, 2020
An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress.
Journal: Molecular therapy. Methods & clinical development
Published: October 17, 2018
RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect.
Journal: Molecular therapy. Nucleic acids
Published: May 11, 2017
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy.
Journal: Nature communications
Published: August 18, 2016
Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.
Journal: Journal of neuromuscular diseases
Published: September 02, 2015
Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy.
Journal: NMR in biomedicine
Published: October 22, 2014
Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 28, 2014
Distinctive serum miRNA profile in mouse models of striated muscular pathologies.
Journal: PloS one
Published: July 23, 2012
A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.
Journal: Brain : a journal of neurology
Published: January 14, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026